Sinovac vaccine may not trigger sufficient antibody response to Brazil variant: study

Plasma samples taken from eight people vaccinated with Sinovac’s CoronaVac failed to efficiently neutralize the P.1 lineage variant according to a paper published on Monday ahead of peer-review.

RIO DE JANEIRO, BRAZIL - Sinovac Biotech’s COVID-19 vaccine may not trigger sufficient antibody responses against a new variant identified in Brazil, a small-sample lab study showed.

The emergence of variants of the new coronavirus has raised concern that vaccines and treatments that were developed based on previous strains may not work as robustly.

Plasma samples taken from eight people vaccinated with Sinovac’s CoronaVac failed to efficiently neutralize the P.1 lineage variant, or 20J/501Y.V3, researchers said in a paper published on Monday ahead of peer-review.

“These results suggest that P.1 virus might . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?